COVID-19 Disease & Vaccine Survey in Africa
COVID-19 Disease & Vaccine Survey in Sub-Saharan Africa
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The coronavirus disease 2019 (COVID-19) pandemic remains a major public health concern. There is inadequate data on the epidemiology of COVID-19 in Africa. There are emerging COVID-19 variants with high transmissibility and morbidity. The World Health Organization (WHO) recommends protective measures and vaccination; for the control of COVID-19. There is inadequate data on the impact of COVID-19 vaccination and control measures in many nations in Africa.
This study is a survey of specific urban populations in sub-Saharan Africa. The anonymized survey is collecting data about people's knowledge and attitude regarding COVID-19 disease or control measures. The survey is also collecting data about people's knowledge, attitude and compliance regarding COVID-19 vaccines. The study uses a validated questionnaire to collect data. The study aims to inform and improve COVID-19 management or control in Africa.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Olu Bamgbade, MD,FRCPC
- Phone Number: 17786286600
- Email: salem.painclinic@gmail.com
Study Contact Backup
- Name: Olumuyiwa Bamgbade, MD,FRCPC
- Phone Number: 17786286600
- Email: salem.painclinic@gmail.com
Study Locations
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3S 7J1
- Salem Anaesthesia Pain Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- urban population in Africa
- people in sub-Saharan Africa town
Exclusion Criteria:
- rural population
- people outside sub-Saharan Africa
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Urban population Africa
Urban population in sub-Saharan Africa
|
Questionnaire survey for data collection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of people who know about COVID-19 prevention
Time Frame: 6 months
|
Percentage of people who know about COVID-19 preventive measures
|
6 months
|
|
Percentage of people who received COVID-19 vaccination
Time Frame: 6 months
|
Percentage of people who received COVID-19 vaccination, 1st and 2nd doses
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Olu Bamgbade, MD,FRCPC, Salem Anaesthesia Pain Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SalemAnes2021 COVID Africa
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
NCT06923137Active, not recruitingCOVID-19 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | COVID-19 Vaccines | SARS-CoV-2 Infection, COVID19 | COVID-19 Vaccination | SARS-CoV-2 Infection, COVID-19 | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 Infection
-
NCT06768697Not yet recruiting
-
NCT07110714RecruitingPost COVID-19 Condition | Post COVID-19 | Post COVID-19 Syndrome | Long COVID-19 Syndrome | Post COVID-19 Condition (PCC)
-
NCT07552779RecruitingRespiratory Tract Diseases | COVID-19 | Pneumonia | Lung Diseases | Coronavirus Disease 2019 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | Upper Respiratory Tract Infections | Respiratory Tract Infection | COVID-19 (Coronavirus Disease 2019)
-
NCT07445971RecruitingCOVID -19 | COVID-19 (Prevention)
-
NCT06156176RecruitingFatigue | Post-COVID-19 Syndrome | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19 | Long-COVID | Post-COVID Condition
-
NCT06294756CompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 Syndrome
-
NCT05839236Active, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated Stroke
-
NCT05817032RecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19
Clinical Trials on Questionnaire
-
NCT03840109CompletedAnxiety | Psychological Stress
-
NCT01260792CompletedGeneral Population | TDAH | Children Aged 5 to 18 Years
-
NCT02576483RecruitingAstigmatism | Nearsightedness | Farsightedness
-
NCT06618898CompletedOrofacial Pain | Sleep Problems
-
NCT04498507CompletedCritical Illness | Covid19 | Psychological Stress | Family
-
NCT05099627Not yet recruitingCervical Myelopathy
-
NCT07482982CompletedFirearm Injury | Firearm Safety | Firearm Ownership
-
NCT06448936Recruiting
-
NCT06466200CompletedQuality of Life | Dentin Hypersensitivity